India's Glenmark Pharma reports lower Q4 profit as domestic sales weaken
Consolidated profit before exceptional items and tax fell to $37.78mln for the three months ended March 31
Stay updated with breaking news from Life Sciences Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Consolidated profit before exceptional items and tax fell to $37.78mln for the three months ended March 31
<iframe src=https://www.youtube.com/embed/h8lhg1Y22Ko></iframe>Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new research note on clinical-stage... | May 5, 2023
The Board of Directors of Glenmark Life Sciences Limited, at its meeting held today have approved the financial results of the company for the period ended March 31, 2023 - Q4FY23 and FY2023.
LONDON, UK / ACCESSWIRE / April 19, 2023 / Tiziana Life Sciences (NASDAQ:TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3
Tiziana Life Sciences Ltd (NASDAQ:TLSA – Get Rating) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 143,100 shares, a growth of 213.1% from the March 15th total of 45,700 shares. Based on an average daily trading volume, of 83,400 […]